Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer

• Robert E. Reiter

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Zhennen Gu

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Tetsuro Watabe

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• George Thomas

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Kinga Szigeti

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Elizabeth Davis

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Matthew Wahl

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Sazuku Nisitani

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Joyce Yamashiro

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Michelle M. Le Beau

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Massimo Loda

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

• Owen N. Witte

  Departments of Urology, Howard Hughes Medical Institute, and Microbiology and Molecular Genetics and Molecular Biology Institute, University of California, Los Angeles, CA 90095; Section of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637; and Department of Pathology, Beth Israel-Deaconess Medical Center-Harvard Medical School, Boston, MA 02215

抄録

The identification of cell surface antigens is critical to the development of new diagnostic and therapeutic modalities for the management of prostate cancer. Prostate stem cell antigen (PSCA) is a prostate-specific gene with 30% homology to stem cell antigen 2, a member of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored cell surface antigens. PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites. PSCA mRNA expression is prostate-specific in normal male tissues and is highly up-regulated in both androgen-dependent and -independent prostate cancer xenografts. In situ mRNA analysis localizes PSCA expression in normal prostate to the basal cell epithelium, the putative stem cell compartment of the prostate. There is moderate to strong PSCA expression in 111 of 126 (88%) prostate cancer specimens examined by in situ analysis, including high-grade prostatic intraepithelial neoplasia and androgen-dependent and androgen-independent tumors. Flow cytometric analysis demonstrates that PSCA is expressed predominantly on the cell surface and is anchored by a GPI linkage. Fluorescent in situ hybridization analysis localizes the PSCA gene to chromosome 8q24.2, a region of allelic gain in more than 80% of prostate cancers. A mouse homologue with 70% amino acid identity and similar genomic organization to human PSCA has also been identified. These results support PSCA as a target for prostate cancer diagnosis and therapy.

収録刊行物

• Proceedings of the National Academy of Sciences

  Proceedings of the National Academy of Sciences 95 (4), 1735-1740, 1998-02-17

  Proceedings of the National Academy of Sciences

キーワード

• Multidisciplinary

詳細情報

• CRID: 1361699993653259520
• NII論文ID: 80010184825
• DOI: 10.1073/pnas.95.4.1735
• ISSN: 10916490
• ISSN: 00278424
• Web Site: https://pnas.org/doi/pdf/10.1073/pnas.95.4.1735
• データソース種別:
  • Crossref
  • CiNii Articles